knowledge -WSS

knowledge

author：focus 2025-09-06 03:52:50 - browse：29474

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： SCOTUS to consider access to abortion pill mifepristone

WSS

Teach medical students about patients with intellectual disabilities

Pfizer plans to depart BIO

CMS should re

Why sickle cell disease is getting the first CRISPR treatment

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

STAT letters to the editor on burnt

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

Walensky prepares to leave CDC — and Congress — behind

In areas with more Black doctors, Black people live longer

Guidelines to prevent youth baseball injuries need more muscle

Spinal cord stimulation reduces pain in amputees, study finds

Hepatitis C has a cure — but many Americans still lack access to it

Leukemia patients are helped by Syndax's new type of therapy

Duchenne breakthrough therapy leaves behind pioneering families

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

The high cost of giving birth even with insurance

Supreme Court wrestles with OxyContin maker's bankruptcy deal

focus

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Leukemia patients are helped by Syndax's new type of therapy

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Weight bias in eating disorder treatment complicated by new weight loss drugs

In areas with more Black doctors, Black people live longer

Supreme Court wrestles with OxyContin maker's bankruptcy deal

hotspot

hotspot

leisure time

focus